Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akso Health GroupAHG -8.85%36 3-Year EBITDA Growth Rate is 85.30% as of Mar. 2026, which is 120% above its 10-year median of 38.80. GuruFocus rates AHG with a GF Score™ of 36/100 and a GF Value™ of $0.39 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 105 Medical Distribution companies, Akso Health Group ranks better than 97.14% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 85.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 59.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Akso Health Group was 85.30% per year. The lowest was -11.80% per year. And the median was 38.80% per year.
Akso Health Group (NAS:AHG) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Akso Health Group 3-Year EBITDA Growth Rate Related Terms
AHG vs ACH, FOCL, YI: 3-Year EBITDA Growth Rate Comparison
For the Medical Distribution subindustry, Akso Health Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akso Health Group 3-Year EBITDA Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Akso Health Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Akso Health Group's 3-Year EBITDA Growth Rate falls into.
Akso Health Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 85.30% mean?
Akso Health Group (AHG) has a 3-Year EBITDA Growth Rate of 85.30% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Akso Health Group and its competitors. This is 120% above median its historical median of 38.80. According to the industry distribution chart, Akso Health Group ranks #3 out of 105 companies in the Medical Distribution industry, placing it in the top 2.9%.
Is Akso Health Group's 3-Year EBITDA Growth Rate too high?
Akso Health Group's current 3-Year EBITDA Growth Rate of 85.30% is 120% above median its 10-year median of 38.80. The Medical Distribution industry median 3-Year EBITDA Growth Rate is 5.40. Akso Health Group's value of 85.30% is 1479.6% above this industry median. Based on the distribution chart, Akso Health Group ranks #3 out of 105 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Akso Health Group has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Akso Health Group's 3-Year EBITDA Growth Rate compare to ACH and FOCL?
According to the Medical Distribution industry distribution chart, Akso Health Group ranks #3 out of 105 companies for 3-Year EBITDA Growth Rate. This places Akso Health Group in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 5.40. Akso Health Group's value of 85.30% is 1479.6% above this benchmark. While the company's 10-year median is 38.80 vs. the industry median of 5.40, Akso Health Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Distribution company?
The median 3-Year EBITDA Growth Rate among Medical Distribution companies is 5.40, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akso Health Group's current 3-Year EBITDA Growth Rate of 85.30% is 1479.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Akso Health Group and its competitors. For the Medical Distribution industry, the median 3-Year EBITDA Growth Rate is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akso Health Group's current 3-Year EBITDA Growth Rate is 85.30%, which is 120% above median its own 10-year median of 38.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akso Health Group stock overvalued right now?
Based on GuruFocus' analysis, Akso Health Group (AHG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.39, compared to a current price of $0.93 — trading 138.4% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 85.30%, which is 120% above median its 10-year median of 38.80 and 1479.6% above the Medical Distribution industry median of 5.40. Akso Health Group's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Akso Health Group (AHG), the current 3-Year EBITDA Growth Rate is 85.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akso Health Group (AHG) Overvalued in 2026?
Based on GuruFocus' analysis, Akso Health Group stock appears to be overvalued.
The current stock price of $0.93 is trading 138.4% above its estimated GF Value™ of $0.39.
GuruFocus considers Akso Health Group to be Significantly Overvalued.
Key valuation signals for AHG:
3-Year EBITDA Growth Rate: 85.30% (120% above median its 10-year median of 38.80)
GF Value™: $0.39 vs. price of $0.93 (138.4% above fair value)
Industry Position: 1479.6% above the Medical Distribution median (#3 of 105)
No single metric tells the full story. See the AHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
36GF Score
Get the complete analysis for AHG
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AHG has been successfully added to your 
